Genor Biopharma Holdings (HKSE:06998) Other Income (Expense) : HK$-15.62 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Other Income (Expense)?

Genor Biopharma Holdings's other income expense for the Genor Biopharma Holdings's pretax income for the six months ended in Jun. 2024 was HK$4.34 Mil. Its other income expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-15.62 Mil.

Genor Biopharma Holdings Other Income (Expense) Historical Data

The historical data trend for Genor Biopharma Holdings's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Other Income (Expense) Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

Get a 7-Day Free Trial

-6.31

-2,501.20

38.26

32.04

-18.17

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Income (Expense)	Get a 7-Day Free Trial						5.37	26.92	1.79	-19.96	4.34

Genor Biopharma Holdings Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-15.62 Mil.

Genor Biopharma Holdings (HKSE:06998) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

67N0:Germany

Address

690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Hillhouse Investment Management, Ltd.	2102 Investment manager
Hhjh Holdings Limited	2101 Beneficial owner
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hh Bio Investment Fund, L.p.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager
Hh Bio Investment Fund L.p.	2201 Interest of corporation controlled by you
Temasek Capital (private) Limited
Aranda Investments Pte. Ltd.
Seletar Investments Pte Ltd
Walga Biotechnology Limited	2101 Beneficial owner
Shang Hai Wo Jia Sheng Wu Ji Shu You Xian Gong Si	2201 Interest of corporation controlled by you
Yun Nan Wo Sen Sheng Wu Ji Shu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited

Genor Biopharma Holdings Headlines

No Headlines